A Phase 2 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Ogeda S.A.. Completed at 8 sites in Belgium. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-27.
Sponsored by Ogeda S.A. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.
Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 2, and was the 8th registered.
339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.
Browse Hot Flashes studies →4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:
Astellas Pharma Inc · Sites in India
Ages 18+ · Women only
University of Colorado, Denver · Sites in United States
Ages 45–55 · Women only · Healthy volunteers
University of Vermont · Sites in United States
Ages 18+ · Men only
Rebecca Thurston · Sites in United States
Ages 40–65 · Women only
By country, each count listing its studies:
fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 40 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 11
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is close to the median of 90 across 306 interventional studies indexed under Hot Flashes.
Median enrollment 249 across the 16 interventional studies. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 7 most frequent:
This study is registered under Ogeda S.A., one of the names counted as Astellas Pharma Inc. Under that name alone:
This is the only study on the registry with Ogeda S.A. as lead sponsor.
16 studies in Hot Flashes by Astellas Pharma Inc: 2 open now, 3 under way, 2 of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 16 studies in Hot Flashes by Astellas Pharma Inc, this one is the 13th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2015, is one of 4 in phase 2, and was the 8th registered.
Astellas Pharma Inc’s Hot Flashes studies by the year they started, since 2015.
1 of the studies testing fezolinetant in Hot Flashes that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972875University of VermontFezolinetant for Treating Hot Flashes in Men With Prostate Cancer | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing fezolinetant in Hot Flashes, from their registry updates:
Among Astellas Pharma Inc’s 16 in Hot Flashes:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to evaluate the effect of ESN364 on the severity and frequency of hot flashes in early postmenopausal women suffering from hot flashes, in terms of changes in weekly Hot Flash Score from baseline to Week 12.
This study also evaluated the effect of ESN364 on the severity and frequency of hot flashes at additional timepoints; hot flash interference on daily life, in terms of changes from baseline over time in Hot Flash Related Daily Interference Scale (HFRDIS); the effect of ESN364 on climacteric symptoms, in terms of changes from baseline over time in Leeds Sleep Evaluation Questionnaire (LSEQ), Greene Climacteric Scale (GCS), and Sheehan Disability Scale (SDS); pharmacodynamic (PD) effect; and safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 90 milligrams (mg) fezolinetant capsules orally, twice daily (BID) for a period of 12 weeks
Drug: Fezolinetant
Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.
Drug: Placebo
Oral Capsule
Also known as: ESN364, ASP2693
Oral Capsule
Change From Baseline to Week 12 in The Weekly General Hot Flash Score
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant dependent for both number and severity.
Time frame: Baseline and week 12
Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 1)
The HF Severity Score by method 1 takes into account the number and severity of moderate and severe HF occurred during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\]/(number of moderate HF + number of severe HF) The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 2)
The HF Severity Score by method 2 takes into account moderate and severe HF during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\] The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in The Weekly Mild, Moderate and Severe Hot Flash Frequency at Weeks 4, 8 and 12
The weekly HF frequency was calculated as number of mild, moderate and severe hot flashes over the week. * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of hot flashes is worse.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=70% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=80% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=90% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HF is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=50% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=70% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
Time frame: Baseline and weeks 4, 8 and 12
Percentage of Participants With >=90% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Hot Flash Related Daily Interference Scale (HFRDIS) Score at Weeks 4, 8 and 12
The HFRDIS was a 10-item scale which measured a woman's perceptions of the degree to which HF interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, enjoying life); the 10th item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory both of which assessed the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which HF had interfered with each item during the previous 4-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score was calculated as sum of items/number of available items. Higher score indicate a higher interference.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Leeds Sleep Evaluation Questionnaire (LSEQ) at Weeks 4, 8 and 12
The LSEQ was a 10-item self-rated questionnaire which assessed participants aspects of sleep and early morning behavior. The questions were grouped into 4 chronological areas: the ease of getting to sleep, the perceived quality of sleep, the ease of awaking from sleep, and the integrity of early morning behavior following wakefulness. The LSEQ was a visual analogue scale which requires respondents to place marks on a group of 10 cm lines. representing the changes they have experienced in a variety of symptoms since the beginning of treatment. Lines extends between extremes like "more difficult than usual" and "easier than usual". Responses are measured using a 100-mm scale and are averaged to provide a score for each domain.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8 and 12
The GCS was a 21-item scale which provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item was rated by the participant according to its severity using a four-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into three main independent symptom measures: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and vasomotor symptoms (items 19 to 20; score 0 to 6), by summing up the individual item scores. Item 21 is a probe for sexual dysfunction (Loss of interest in sex). The total score ranges from 0 to 63. Higher scores indicate worse symptoms.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12
The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms on a 10-point visual analog scale. The 3 items could be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).Higher scores indicate significant functional impairment.
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12 (Days Lost and Days Unproductive)
The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms. In addition to the 3 items, the participants were asked two questions Days Lost: On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities? Day Unproductive: On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work, your productivity was reduced?
Time frame: Baseline and weeks 4, 8 and 12
Change From Baseline in Plasma Concentration of Luteinizing Hormone (LH)
Change From baseline in plasma concentration of LH was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12: 3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Follicle-Stimulating Hormone (FSH)
Change From baseline in plasma concentration of FSH was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Estradiol (E2)
Change From baseline in plasma concentration of E2 was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Sex Hormone-Binding Globulin (SHBG)
Change From baseline in plasma concentration of SHBG was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Leptin
Change From baseline in plasma concentration of leptin was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Insulin
Change From baseline in plasma concentration of insulin was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of C-peptide
Change From baseline in plasma concentration of C-peptide was reported.
Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Change From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c)
Change From baseline in plasma concentration of HBA1C was reported.
Time frame: Baseline and week 12
Number of Participants With Adverse Events (AE's)
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inparticipant hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to end of study.
Time frame: From first dose of study drug until end of the study (Up to week 15)
Change From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 12
Change from baseline in plasma concentration of BALP was reported.
Time frame: Baseline and week 12
Change From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12
Change from baseline in plasma concentration of CTX was reported.
Time frame: Baseline and week 12
Postmenopausal women participants between 40 to 65 years of age who had hot flashes (HF) and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.
| Milestone | Placebo | Fezolinetant |
|---|---|---|
| Started | 44 | 43 |
| Completed | 40 | 40 |
| Not completed | 4 | 3 |
| Withdrew: Participant did not fulfill all inclusion/exclusion criteria | 1 | 0 |
| Withdrew: Serious adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Miscellaneous | 1 | 1 |
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant dependent for both number and severity.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Change From Baseline to Week 12 in The Weekly General Hot Flash Score | -12.19 (-16.55 to -7.83) | -26.51 (-30.83 to -22.18) |
The HF Severity Score by method 1 takes into account the number and severity of moderate and severe HF occurred during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\]/(number of moderate HF + number of severe HF) The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | -0.294 (-0.473 to -0.116) | -1.428 (-1.718 to -1.138) |
| Week 8 | -0.608 (-0.899 to -0.318) | -1.557 (-1.858 to -1.257) |
| Week 12 | -0.534 (-0.798 to -0.270) | -1.656 (-1.937 to -1.376) |
The HF Severity Score by method 2 takes into account moderate and severe HF during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\] The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | -9.55 (-12.73 to -6.36) | -25.26 (-29.64 to -20.89) |
| Week 8 | -11.91 (-15.72 to -8.10) | -25.71 (-30.15 to -21.27) |
| Week 12 | -12.14 (-16.62 to -7.65) | -26.61 (-31.06 to -22.17) |
The weekly HF frequency was calculated as number of mild, moderate and severe hot flashes over the week. * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of hot flashes is worse.
| HF's per day | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | -26.4 (-35.2 to -17.5) | -72.3 (-82.7 to -61.8) |
| Week 8 | -32.9 (-43.2 to -22.7) | -73.3 (-83.8 to -62.8) |
| Week 12 | -35.6 (-46.7 to -24.5) | -75.3 (-86.4 to -64.3) |
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 22.7 (10.34 to 35.11) | 87.8 (77.79 to 97.82) |
| Week 8 | 39.0 (24.09 to 53.96) | 87.5 (77.25 to 97.75) |
| Week 12 | 42.5 (27.18 to 57.82) | 95.0 (88.25 to 100.00) |
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 9.1 (0.60 to 17.59) | 78.0 (65.38 to 90.72) |
| Week 8 | 26.8 (13.27 to 40.39) | 77.5 (64.56 to 90.44) |
| Week 12 | 30.0 (15.80 to 44.20) | 87.5 (77.25 to 97.75) |
The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HF is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 6.8 (0.00 to 14.27) | 61.0 (46.04 to 75.91) |
| Week 8 | 12.2 (2.18 to 22.21) | 60.0 (44.82 to 75.18) |
| Week 12 | 15.0 (3.93 to 26.07) | 62.5 (47.50 to 77.50) |
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 45.5 (30.74 to 60.17) | 95.1 (88.53 to 100.00) |
| Week 8 | 53.7 (38.39 to 68.92) | 97.5 (92.66 to 100.00) |
| Week 12 | 55.0 (39.58 to 70.42) | 97.5 (92.66 to 100.00) |
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 25.0 (12.21 to 37.79) | 87.8 (77.79 to 97.82) |
| Week 8 | 46.3 (31.08 to 61.61) | 92.5 (84.34 to 100.00) |
| Week 12 | 40.0 (24.82 to 55.18) | 97.5 (92.66 to 100.00) |
The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.
| percentage of participants | Placebo | Fezolinetant |
|---|---|---|
| Week 4 | 6.8 (0.00 to 14.27) | 68.3 (54.05 to 82.54) |
| Week 8 | 24.4 (11.25 to 37.54) | 67.5 (52.99 to 82.01) |
| Week 12 | 20.0 (7.60 to 32.40) | 72.5 (58.66 to 86.34) |
The HFRDIS was a 10-item scale which measured a woman's perceptions of the degree to which HF interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, enjoying life); the 10th item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory both of which assessed the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which HF had interfered with each item during the previous 4-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score was calculated as sum of items/number of available items. Higher score indicate a higher interference.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Work | -1.7 ± 2.93 | -4.6 ± 2.65 |
| Week 8: Work | -2.4 ± 2.80 | -5.0 ± 2.38 |
| Week 12: Work | -2.3 ± 2.58 | -4.6 ± 2.68 |
| Week 4: Social Activities | -1.6 ± 2.53 | -4.3 ± 2.48 |
| Week 8: Social Activities | -1.9 ± 2.85 | -4.7 ± 2.37 |
| Week 12: Social Activities | -1.8 ± 2.51 | -4.3 ± 2.35 |
| Week 4: Leisure Activities | -1.6 ± 2.63 | -4.0 ± 2.51 |
| Week 8: Leisure Activities | -1.7 ± 2.72 | -4.2 ± 2.50 |
| Week 12: Leisure Activities | -2.0 ± 2.52 | -3.8 ± 3.08 |
| Week 4: Sleep | -2.5 ± 2.93 | -5.2 ± 2.77 |
| Week 8: Sleep | -3.2 ± 3.29 | -5.7 ± 2.37 |
| Week 12: Sleep | -3.3 ± 3.01 | -5.8 ± 2.43 |
| Week 4: Mood | -2.3 ± 2.49 | -4.0 ± 2.85 |
| Week 8: Mood | -2.3 ± 2.86 | -4.4 ± 2.84 |
| Week 12: Mood | -2.5 ± 2.56 | -4.3 ± 2.64 |
| Week 4: Concentration | -1.6 ± 2.68 | -3.9 ± 2.57 |
| Week 8: Concentration | -1.6 ± 3.06 | -4.1 ± 2.59 |
| Week 12: Concentration | -1.9 ± 3.17 | -4.0 ± 2.47 |
| Week 4: Relations With Others | -2.1 ± 2.93 | -3.3 ± 2.45 |
| Week 8: Relations With Others | -1.8 ± 3.02 | -3.5 ± 2.70 |
| Week 12: Relations With Others | -1.8 ± 3.16 | -3.3 ± 2.67 |
| Week 4: Sexuality | -1.9 ± 2.88 | -3.0 ± 3.49 |
| Week 8: Sexuality | -1.8 ± 3.48 | -3.2 ± 3.76 |
| Week 12: Sexuality | -1.7 ± 2.84 | -3.4 ± 3.86 |
| Week 4: Enjoyment of Life | -1.6 ± 2.86 | -3.6 ± 2.65 |
| Week 8: Enjoyment of Life | -1.5 ± 3.15 | -3.9 ± 2.59 |
| Week 12: Enjoyment of Life | -1.6 ± 3.38 | -3.7 ± 2.42 |
| Week 4: Overall Quality of Life | -1.4 ± 2.43 | -3.8 ± 2.87 |
| Week 8: Overall Quality of Life | -1.5 ± 3.01 | -4.5 ± 1.92 |
| Week 12: Overall Quality of Life | -1.6 ± 3.05 | -4.6 ± 2.16 |
| Week 4: Overall Mean Score | -1.84 ± 1.922 | -3.97 ± 2.141 |
| Week 8: Overall Mean Score | -1.98 ± 2.439 | -4.33 ± 1.945 |
| Week 12: Overall Mean Score | -2.05 ± 2.326 | -4.17 ± 2.067 |
The LSEQ was a 10-item self-rated questionnaire which assessed participants aspects of sleep and early morning behavior. The questions were grouped into 4 chronological areas: the ease of getting to sleep, the perceived quality of sleep, the ease of awaking from sleep, and the integrity of early morning behavior following wakefulness. The LSEQ was a visual analogue scale which requires respondents to place marks on a group of 10 cm lines. representing the changes they have experienced in a variety of symptoms since the beginning of treatment. Lines extends between extremes like "more difficult than usual" and "easier than usual". Responses are measured using a 100-mm scale and are averaged to provide a score for each domain.
| millimeter (mm) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Getting to Sleep | 1.017 ± 1.9195 | 2.283 ± 2.7364 |
| Week 8: Getting to Sleep | 1.145 ± 1.7931 | 2.248 ± 2.5233 |
| Week 12: Getting to Sleep | 1.282 ± 1.7761 | 2.094 ± 2.4419 |
| Week 4: Quality of Sleep | 2.145 ± 2.6443 | 4.437 ± 4.0768 |
| Week 8: Quality of Sleep | 2.378 ± 2.8160 | 4.703 ± 3.1971 |
| Week 12: Quality of Sleep | 1.904 ± 2.7872 | 4.385 ± 3.4477 |
| Week 4: Awake Following Sleep | 0.642 ± 2.0739 | 2.180 ± 3.0579 |
| Week 8: Awake Following Sleep | 0.653 ± 2.5019 | 2.920 ± 3.0219 |
| Week 12: Awake Following Sleep | 1.024 ± 2.6114 | 2.887 ± 3.1333 |
| Week 4: Behavior Following Wakening | 1.173 ± 2.1743 | 2.513 ± 2.7919 |
| Week 8: Behavior Following Wakening | 0.750 ± 2.6371 | 2.539 ± 2.7742 |
| Week 12: Behavior Following Wakening | 1.203 ± 2.5185 | 2.233 ± 2.8190 |
The GCS was a 21-item scale which provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item was rated by the participant according to its severity using a four-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into three main independent symptom measures: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and vasomotor symptoms (items 19 to 20; score 0 to 6), by summing up the individual item scores. Item 21 is a probe for sexual dysfunction (Loss of interest in sex). The total score ranges from 0 to 63. Higher scores indicate worse symptoms.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Loss of Interest in Sex | -0.4 ± 0.67 | -0.5 ± 0.88 |
| Week 8: Loss of interest in Sex | -0.5 ± 0.85 | -0.7 ± 1.15 |
| Week 12: Loss of Interest in Sex | -0.4 ± 0.75 | -0.6 ± 1.14 |
| Week 4: Psychological | -2.3 ± 5.22 | -5.3 ± 5.97 |
| Week 8: Psychological | -2.6 ± 5.31 | -6.7 ± 6.49 |
| Week 12: Psychological | -2.9 ± 5.14 | -6.6 ± 6.03 |
| Week 4: Physical | -2.1 ± 3.68 | -1.2 ± 2.71 |
| Week 8: Physical | -1.9 ± 3.46 | -1.9 ± 3.09 |
| Week 12: Physical | -2.4 ± 3.80 | -1.9 ± 3.32 |
| Week 4: Vasomotor | -1.1 ± 1.79 | -3.3 ± 1.83 |
| Week 8: Vasomotor | -1.7 ± 2.23 | -3.6 ± 1.48 |
| Week 12: Vasomotor | -1.5 ± 2.31 | -3.6 ± 1.37 |
| Week 4: Total Symptom Score | -5.5 ± 9.33 | -9.9 ± 9.24 |
| Week 8: Total Symptom Score | -5.8 ± 8.89 | -13.1 ± 10.68 |
| Week 12: Total Symptom Score | -6.3 ± 8.87 | -13.1 ± 10.04 |
The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms on a 10-point visual analog scale. The 3 items could be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).Higher scores indicate significant functional impairment.
| score on a scale | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Work/School | -1.3 ± 2.43 | -3.6 ± 2.78 |
| Week 8: Work/School | -1.7 ± 2.56 | -4.4 ± 2.43 |
| Week 12: Work/School | -1.8 ± 2.76 | -4.3 ± 2.47 |
| Week 4: Social Life | -1.2 ± 2.35 | -3.3 ± 2.60 |
| Week 8: Social Life | -1.3 ± 2.57 | -3.8 ± 2.79 |
| Week 12: Social Life | -1.5 ± 2.55 | -3.6 ± 2.51 |
| Week 4: Family Life/Home Responsibilities | -1.5 ± 2.70 | -3.3 ± 2.97 |
| Week 8: Family Life/Home Responsibilities | -1.7 ± 2.64 | -4.0 ± 2.83 |
| Week 12: Family Life/Home Responsibilities | -1.7 ± 2.38 | -3.7 ± 2.65 |
| Week 4: Global Functional Impairment | -3.7 ± 5.50 | -9.6 ± 6.99 |
| Week 8: Global Functional Impairment | -4.5 ± 6.87 | -12.3 ± 6.42 |
| Week 12: Global Functional Impairment | -4.8 ± 6.49 | -11.8 ± 6.35 |
The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms. In addition to the 3 items, the participants were asked two questions Days Lost: On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities? Day Unproductive: On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work, your productivity was reduced?
| days | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Days Lost | -0.2 ± 1.27 | 0.0 ± 0.73 |
| Week 8: Days Lost | -0.3 ± 0.81 | 0.0 ± 0.00 |
| Week 12: Days Lost | -0.2 ± 1.18 | 0.0 ± 0.00 |
| Week 4: Days Unproductive | -0.8 ± 2.83 | -1.7 ± 2.67 |
| Week 8: Days Unproductive | -1.2 ± 3.10 | -2.0 ± 2.55 |
| Week 12: Days Unproductive | -1.4 ± 2.82 | -2.2 ± 2.59 |
Change From baseline in plasma concentration of LH was reported.
| international unit per liter (IU/L) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | -2.34 ± 9.350 | -8.84 ± 10.865 |
| Week 8: Pre-dose | -3.86 ± 9.838 | -9.46 ± 13.647 |
| Week 12: Pre-dose | -4.61 ± 13.304 | -9.72 ± 12.834 |
| Week 12: 3 hours (h) | -7.16 ± 13.009 | -21.78 ± 11.923 |
| Week 15 | -6.16 ± 14.197 | -3.33 ± 11.742 |
Change From baseline in plasma concentration of FSH was reported.
| IU/L | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | -5.80 ± 19.430 | -3.44 ± 18.026 |
| Week 8: Pre-dose | -6.60 ± 20.086 | -10.36 ± 23.943 |
| Week 12: Pre-dose | -7.05 ± 19.978 | -10.51 ± 24.521 |
| Week 12: 3h | -8.47 ± 19.159 | -19.48 ± 22.734 |
| Week 15 | -6.50 ± 21.011 | -6.97 ± 22.273 |
Change From baseline in plasma concentration of E2 was reported.
| Picomoles per liter (pmol/L) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | 18.4 ± 140.36 | -7.3 ± 75.13 |
| Week 8: Pre-dose | 26.0 ± 157.18 | 1.0 ± 71.78 |
| Week 12: Pre-dose | 32.3 ± 101.87 | 25.5 ± 108.27 |
| Week 12: 3h | 26.0 ± 100.33 | 11.5 ± 77.68 |
| Week 15 | 37.0 ± 167.37 | 27.9 ± 188.18 |
Change From baseline in plasma concentration of SHBG was reported.
| Nanomoles per liter (nmol/L) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | 0.61 ± 16.260 | -0.47 ± 11.986 |
| Week 8: Pre-dose | 5.10 ± 20.713 | -1.37 ± 12.186 |
| Week 12: Pre-dose | 1.75 ± 18.090 | 0.36 ± 15.165 |
| Week 12: 3h | 1.56 ± 18.658 | -1.49 ± 16.406 |
| Week 15 | 1.92 ± 16.341 | -0.86 ± 13.540 |
Change From baseline in plasma concentration of leptin was reported.
| nanogram per liter (ng/mL) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | 1.2436 ± 5.6269 | -2.2185 ± 6.9522 |
| Week 8: Pre-dose | 1.6225 ± 7.5029 | -1.7090 ± 6.9716 |
| Week 12: Pre-dose | 0.9668 ± 5.4301 | -0.4183 ± 11.0737 |
| Week 12: 3h | -2.0755 ± 5.3193 | -4.2085 ± 8.5335 |
| Week 15 | -0.9914 ± 14.6660 | -0.6031 ± 8.2519 |
Change From baseline in plasma concentration of insulin was reported.
| micro units per milliliter (μU/mL) | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | -0.2767 ± 3.0971 | -0.7512 ± 3.8798 |
| Week 8: Pre-dose | 0.3525 ± 4.0903 | -0.5325 ± 3.6121 |
| Week 12: Pre-dose | -0.0825 ± 3.1593 | 0.1300 ± 4.7942 |
| Week 12: 3h | 16.3225 ± 19.0210 | 14.4950 ± 19.2787 |
| Week 15 | 0.3256 ± 4.1132 | -0.1595 ± 3.1071 |
Change From baseline in plasma concentration of C-peptide was reported.
| ng/mL | Placebo | Fezolinetant |
|---|---|---|
| Week 4: Pre-dose | -0.0465 ± 0.3978 | -0.1463 ± 0.5134 |
| Week 8: Pre-dose | -0.0300 ± 0.5273 | -0.1175 ± 0.4750 |
| Week 12: Pre-dose | -0.0750 ± 0.5212 | -0.0425 ± 0.7154 |
| Week 12: 3h | 2.1325 ± 1.9976 | 2.2875 ± 2.1811 |
| Week 15 | -0.0047 ± 0.6102 | -0.0095 ± 0.4023 |
Change From baseline in plasma concentration of HBA1C was reported.
| Percentage of HBA1c | Placebo | Fezolinetant |
|---|---|---|
| Change From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c) | -0.00050000 ± 0.003162278 | -0.002307692 ± 0.004845800 |
An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inparticipant hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to end of study.
| participants | Placebo | Fezolinetant |
|---|---|---|
| At least one TEAE | 35 | 29 |
| At least one serious TEAE | 1 | 0 |
| At least one TEAE leading to death | 0 | 0 |
| At least one severe TEAE | 0 | 0 |
| At least one TEAE for which the study treatment was permanently stopped | 0 | 2 |
| At least one TEAE that was considered treatment related | 11 | 13 |
Change from baseline in plasma concentration of BALP was reported.
| microgram per milliliter (ug/mL) | Placebo | Fezolinetant |
|---|---|---|
| Change From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 12 | 2.9 ± 5.43 | 1.7 ± 3.19 |
Change from baseline in plasma concentration of CTX was reported.
| ug/mL | Placebo | Fezolinetant |
|---|---|---|
| Change From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12 | -0.021 ± 0.1278 | 0.001 ± 0.1356 |
Collected over From first dose of study drug until end of the study (Up to week 15). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/44 (0%) | 1/44 (2.3%) | 18/44 (40.9%) |
| Fezolinetant | 0/43 (0%) | 0/43 (0%) | 18/43 (41.9%) |
| Event | Placebo | Fezolinetant |
|---|---|---|
| Upper limb fractureInjury, poisoning and procedural complications | 1/44 | 0/43 |
| Event | Placebo | Fezolinetant |
|---|---|---|
| HeadacheNervous system disorders | 6/44 | 7/43 |
| NasopharyngitisInfections and infestations | 4/44 | 2/43 |
| PalpitationsCardiac disorders | 2/44 | 3/43 |
| DiarrhoeaGastrointestinal disorders | 0/44 | 3/43 |
| FatigueGeneral disorders | 0/44 | 3/43 |
| InfluenzaInfections and infestations | 1/44 | 3/43 |
| ArthritisMusculoskeletal and connective tissue disorders | 3/44 | 0/43 |
| Back painMusculoskeletal and connective tissue disorders | 3/44 | 0/43 |
Safety population was defined as all participants who were randomized into the study and received at least one dose of the study medication.
| Age, Continuous(Years) | Placebo | Fezolinetant | Total |
|---|---|---|---|
| Mean | 53.7 ± 4.25 | 53.3 ± 4.03 | 53.5 ± 4.12 |
| Sex: Female, Male(Participants) | Placebo | Fezolinetant | Total |
|---|---|---|---|
| Female | 44 | 43 | 87 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Fezolinetant | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 42 | 42 | 84 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Placebo | Fezolinetant | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 44 | 42 | 86 |
| More than one race | 0 | 1 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weekly General Hot Flash Score(Score on a scale) | Placebo | Fezolinetant | Total |
|---|---|---|---|
| Mean | 25.76 ± 10.26 | 28.76 ± 13.39 | 27.24 ± 11.93 |
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Sep 2015 to primary completion in Sep 2016, 12 months.
Results were first posted in Jul 2023, 6 years 10 months after primary completion. A results delay was requested in Jul 2022.
Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fezolinetant